Printed From:

KEVZARA Offers Consistent Every-2-Week Dosing for Your Patients1

Recommended dose is 200 mg every 2 weeks as a subcutaneous injection1

  • Recommended dose is 200 mg every 2 weeks as a subcutaneous injection1

  • KEVZARA can be used with or without MTX or other conventional DMARDs1*

  • Reduce the dose to 150 mg once every 2 weeks for the management of neutropenia, thrombocytopenia, or elevated liver enzymes1

    • Click here for dosing considerations for patient management

*Dosing of MTX and other conventional DMARDs may vary.


KEVZARA Offers 2 Forms of Administration

The Button-Free KEVZARA Pen: Designed With RA Patients in Mind2

REAL-WORLD DATA »

Please click on the "Instructions for Use" (IFU) link above for further information.

KEVZARA® button-free pen 200 mg
KEVZARA® button-free pen 150 mg

KEVZARA Prefilled Syringe

KEVZARA® (sarilumab) 200 mg and 200 mg injectable doses
KEVZARA® (sarilumab) 200 mg and 150 mg injectable doses

KEVZARA is available by prescription only.

Both the KEVZARA prefilled pen and prefilled syringe must be refrigerated, but either can be kept at room temperature for up to 14 days, if needed.1

Ease of Use

The KEVZARA packaging, prefilled pen and prefilled syringe received the Arthritis Foundation Ease of Use Commendation after independent testing by experts and evaluation by people with arthritis. Products receiving the Commendation make certain aspects of life easier for people with RA.3,4

DMARD=disease-modifying antirheumatic drug.

References: 1. KEVZARA [prescribing information]. Bridgewater, NJ: Sanofi/Regeneron Pharmaceuticals, Inc; 2018. 2. Kivitz A, Baret-Cormel L, van Hoogstraten H et al. Usability and patient preference phase 3 study of the sarilumab pen in patients with active moderate-to-severe rheumatoid arthritis. Rheumatol Ther. 2017. doi:10.1007/s40744-017-0090-2. 3. Ease of use products. Arthritis Foundation website. http://www.arthritis.org/living-with-arthritis/tools-resources/ease-of-use. Accessed October 10, 2017. 4. Data on file, Sanofi/Regeneron. Regeneron Sarilumab Evaluation Report of Consumer Product Accessibility for Users with Arthritis. February 2015.